T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.57% |
| 2 | Consumer Discretionary | 13.93% |
| 3 | Financials | 13.16% |
| 4 | Industrials | 12.02% |
| 5 | Technology | 10.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGY
1501
DELISTED
Stone Energy
SGY
| $3.69M | ﹤0.01% |
4,421
-352
| -7% | -$311K |
|
1502
RPC Inc
RES
$1.42B
| $3.67M | ﹤0.01% |
+286,325
| New | +$3.59M |
|
1503
Unisys
UIS
$208M
| $3.63M | ﹤0.01% |
156,339
-16,000
| -9% | -$390K |
|
1504
Qorvo
QRVO
$8.6B
| $3.62M | ﹤0.01% |
+45,471
| New | +$3.24M |
|
1505
Dr. Reddy's Laboratories
RDY
$10.2B
| $3.62M | ﹤0.01% |
316,760
-516,135
| -62% | -$5.47M |
|
1506
Signet Jewelers
SIG
$3.52B
| $3.61M | ﹤0.01% |
26,000
| – | – |
|
1507
Corpay
CPAY
$27.5B
| $3.59M | ﹤0.01% |
23,790
-2,329
| -9% | -$345K |
|
1508
HealthEquity
HQY
$8.77B
| $3.58M | ﹤0.01% |
143,190
+2,790
| +2% | +$60.5K |
|
1509
John Wiley & Sons Class A
WLY
$2.62B
| $3.58M | ﹤0.01% |
58,470
-2,600
| -4% | -$160K |
|
|
DNY
1510
DELISTED
DONNELLEY R R & SONS CO
DNY
| $3.57M | ﹤0.01% |
186,255
+4,600
| +3% | +$88.3K |
|
1511
Cedar Fair
FUN
$1.69B
| $3.57M | ﹤0.01% |
62,135
-19
| -0% | -$1.03K |
|
|
CETV
1512
DELISTED
Central European Media Enterprises Ltd
CETV
| $3.53M | ﹤0.01% |
1,328,700
-4,271,372
| -76% | -$11.7M |
|
1513
Realty Income
O
$59.6B
| $3.51M | ﹤0.01% |
70,120
+340
| +0.5% | +$17K |
|
|
EV
1514
DELISTED
Eaton Vance Corp.
EV
| $3.5M | ﹤0.01% |
84,166
| – | – |
|
|
WFT
1515
DELISTED
Weatherford International plc
WFT
| $3.46M | ﹤0.01% |
281,115
+2,090
| +0.7% | +$24.3K |
|
|
BKYF
1516
DELISTED
BK KY FINL CORP
BKYF
| $3.41M | ﹤0.01% |
69,600
+300
| +0.4% | +$14.2K |
|
1517
Advance Auto Parts
AAP
$3.41B
| $3.41M | ﹤0.01% |
22,755
-10,823
| -32% | -$1.67M |
|
1518
Vanda Pharmaceuticals
VNDA
$317M
| $3.4M | ﹤0.01% |
365,628
-4,209,593
| -92% | -$47.6M |
|
|
GNBC
1519
DELISTED
Green Bancorp, Inc
GNBC
| $3.35M | ﹤0.01% |
300,100
-15,079
| -5% | -$168K |
|
1520
Tennant Co
TNC
$1.18B
| $3.31M | ﹤0.01% |
50,600
| – | – |
|
|
PZN
1521
DELISTED
Pzena Investment Management, Inc. Class A
PZN
| $3.29M | ﹤0.01% |
359,300
+1,400
| +0.4% | +$12.1K |
|
1522
Heartland Express
HTLD
$987M
| $3.29M | ﹤0.01% |
138,319
+5,900
| +4% | +$150K |
|
|
AKAO
1523
DELISTED
Achaogen Inc
AKAO
| $3.24M | ﹤0.01% |
332,341
-62,259
| -16% | -$702K |
|
1524
Expro Ltd
XPRO
$2.11B
| $3.19M | ﹤0.01% |
28,417
-4,916
| -15% | -$498K |
|
|
RENT
1525
DELISTED
RENTRAK CORP
RENT
| $3.02M | ﹤0.01% |
54,300
| – | – |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.